POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Clinical trials for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER explained in plain language.
Never miss a new study
Get alerted when new POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER trials appear
Sign up with your email to follow new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Post-Transplant virus
Disease control Recruiting nowThis study tests a new treatment for Epstein-Barr virus (EBV) infection that can occur after a stem cell transplant. The treatment uses specially engineered immune cells (EBV-TCR-T cells) to target and clear the virus. About 18 adults who have EBV in their blood despite standard …
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated May 17, 2026 02:45 UTC
-
New cell therapy targets dangerous EBV virus in transplant patients
Disease control Recruiting nowThis study tests a new treatment called EBV-AST cells for people who have an EBV virus infection after a stem cell transplant. The goal is to find the safest dose and see if it can clear the virus from the blood. About 18 adults aged 18-75 will take part. The treatment uses speci…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Smart bomb for lymphoma: targeted drug trial seeks to shrink tumors
Disease control Recruiting nowThis phase 2 trial tests whether loncastuximab tesirine can shrink tumors in 20 adults with B-cell lymphomas that have returned or not responded to prior treatment. The drug is a targeted therapy that attaches to a protein on cancer cells and delivers a chemotherapy agent directl…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for transplant patients: combo therapy targets rare cancer without harsh chemo
Disease control Recruiting nowThis study tests a combination of two drugs, polatuzumab vedotin and rituximab, as a first treatment for a rare cancer called post-transplant lymphoproliferative disorder (PTLD) that can occur after an organ or stem cell transplant. The goal is to see if this combo is safe and wo…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 13, 2026 15:59 UTC